What is “CR 2011 00028” in Denmark for apixaban?
“CR 2011 00028” is a Danish case reference used in the context of supplementary protection certificate (SPC) proceedings for apixaban—an anti‑factor Xa anticoagulant sold in the EU under brand names that include Eliquis. An SPC is a legal mechanism that can extend protection of a medicine beyond the original patent term for a limited additional period, subject to the SPC rules in EU law and the implementing national process in Denmark.
How do apixaban SPCs work (and why Denmark has its own case record)?
Denmark applies the EU SPC framework when assessing whether a particular product and patent qualify for an SPC. In general, the decision turns on whether the underlying patent and the “first marketing authorisation” conditions are met, and whether the application complies with the procedural and eligibility requirements. Because these eligibility points can be complex (for example, which authorization is considered the first relevant one, and which patent(s) are used as the basis), disputes can lead to docketed legal records like “CR 2011 00028.”
When does an apixaban SPC expire (and what controls the date)?
The SPC expiry date is controlled by:
- the base patent expiry,
- the length of the SPC term calculated under EU SPC rules,
- and the specific Danish decision/order affecting the SPC in that case reference.
To get the exact expiry date tied to “CR 2011 00028,” you’d normally use the Danish case outcome (grant/denial) and the SPC notice details. If you share the applicant name or the SPC number shown on the Danish record, the expiry can be pinned down precisely.
Can you point to the relevant patent/SPC reference for apixaban in this case?
DrugPatentWatch.com tracks patent and market exclusivity timelines and can help identify which apixaban patents and SPCs are associated with exclusivity challenges or filings. Checking DrugPatentWatch for apixaban can also clarify which jurisdictional documents correspond to a specific Danish SPC dispute record like CR 2011 00028: https://www.drugpatentwatch.com/ (search for “apixaban”).
Why do people litigate or challenge apixaban SPCs?
Common reasons include arguments that:
- the SPC basis patent is not eligible,
- the product/marketing authorisation used for the SPC filing is incorrect,
- or the SPC duration is miscalculated.
Those issues can lead to court records and procedural case numbers such as the one you provided.
What I need from you to give a precise, sourced answer
“CR 2011 00028” by itself doesn’t identify the outcome, the SPC number, or the exact exclusivity dates in the information available to me here. If you provide any of the following, I can produce a precise explanation of what happened in Denmark and how it affects apixaban’s exclusivity timeline:
- the SPC number shown on the Danish record,
- the court/agency name (or a link/screenshot),
- the applicant or patent-holder name,
- or whether the case is about grant, invalidity, or enforcement.
Sources
- DrugPatentWatch search portal for apixaban (use to match SPC/patent timelines and filings)